1. Home
  2. NVT vs VTRS Comparison

NVT vs VTRS Comparison

Compare NVT & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVT
  • VTRS
  • Stock Information
  • Founded
  • NVT 1903
  • VTRS 1961
  • Country
  • NVT United Kingdom
  • VTRS United States
  • Employees
  • NVT N/A
  • VTRS N/A
  • Industry
  • NVT Industrial Machinery/Components
  • VTRS Medicinal Chemicals and Botanical Products
  • Sector
  • NVT Industrials
  • VTRS Health Care
  • Exchange
  • NVT Nasdaq
  • VTRS Nasdaq
  • Market Cap
  • NVT 11.5B
  • VTRS 10.6B
  • IPO Year
  • NVT N/A
  • VTRS N/A
  • Fundamental
  • Price
  • NVT $73.48
  • VTRS $9.34
  • Analyst Decision
  • NVT Strong Buy
  • VTRS Hold
  • Analyst Count
  • NVT 9
  • VTRS 5
  • Target Price
  • NVT $70.33
  • VTRS $10.40
  • AVG Volume (30 Days)
  • NVT 1.7M
  • VTRS 12.4M
  • Earning Date
  • NVT 08-05-2025
  • VTRS 08-07-2025
  • Dividend Yield
  • NVT 1.09%
  • VTRS 5.14%
  • EPS Growth
  • NVT 1.65
  • VTRS N/A
  • EPS
  • NVT 3.49
  • VTRS N/A
  • Revenue
  • NVT $3,083,300,000.00
  • VTRS $14,330,200,000.00
  • Revenue This Year
  • NVT $19.79
  • VTRS N/A
  • Revenue Next Year
  • NVT $9.30
  • VTRS $1.85
  • P/E Ratio
  • NVT $21.01
  • VTRS N/A
  • Revenue Growth
  • NVT 15.90
  • VTRS N/A
  • 52 Week Low
  • NVT $41.71
  • VTRS $6.85
  • 52 Week High
  • NVT $81.55
  • VTRS $13.55
  • Technical
  • Relative Strength Index (RSI)
  • NVT 68.17
  • VTRS 62.77
  • Support Level
  • NVT $71.30
  • VTRS $8.88
  • Resistance Level
  • NVT $74.75
  • VTRS $9.16
  • Average True Range (ATR)
  • NVT 1.70
  • VTRS 0.23
  • MACD
  • NVT 0.00
  • VTRS 0.03
  • Stochastic Oscillator
  • NVT 82.72
  • VTRS 91.28

About NVT nVent Electric plc

nVent is a leading global provider of electrical connection and protection solutions that touches a broad range of end markets including infrastructure, industrial, commercial, and residential. NVent designs, manufacturers, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: